Regeneron Pharmaceuticals Inc
REGNCompany Overview
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Shariah Compliance Benchmarks:
- Business Compliance: Non-Shariah compliant revenue must be less than 5% of total revenue
- Liabilities Compliance: Interest-bearing debt must be less than 33% of market capitalization
This stock meets all Shariah compliance criteria according to AAOIFI standards.
| Name | Regeneron Pharmaceuticals Inc |
| Ticker | REGN |
| Main Business | Biotechnology |
| Type | Common Stock |
| Industry | Biotechnology |
| Country | US |
| Market Cap | $96.52 B |
Shariah Analysis Breakdown
| Revenue Segment | Value ($M) | Non-Compliant ($M) | Reason |
|---|---|---|---|
| EYLEA - United States (U.S.) | $6,260.0 | $0.0 | - |
| Sanofi | $2,860.0 | $0.0 | - |
| Bayer | $1,430.0 | $0.0 | - |
| Roche | $627.3 | $0.0 | - |
| Libtayo | $447.5 | $0.0 | - |
| Other revenue | $365.1 | $0.0 | - |
| Praluent - United States (U.S.) | $130.0 | $0.0 | - |
| Evkeeza - United States (U.S.) | $48.6 | $0.0 | - |
| Inmazeb - United States (U.S.) | $3.0 | $0.0 | - |
| Other | $0.4 | $0.0 | - |
| Interest income | $160.1 | $160.1 | - |
| Total | $12,332.0 | $160.1 | 1.28% (passed) |
| Liability Item | Value ($M) | % of Market Cap |
|---|---|---|
| long term debt and capital lease obligation | $2,700,000,000.0 | 2.80% |
| Total Interest-Bearing Debt | $2,700,000,000.0 | 2.80% |
| Market Capitalization | $96,515,288,100.0 | 100.00% |
| Compliance Status | Threshold: 33% | passed |